Beyond Glucose Control: The Expanding Role of Incretins in Diabetes and Obesity Management


In this MEDcast episode, Diana Isaacs, PharmD, BC-ADM, CDCES, and Natalie Bellini, DNP, FNP-BC, interview Dr Juan Frias to explore the mechanism of GLP-1 and GIP agonists in diabetes and weight management and examine key findings from clinical trials for the latest GLP-1/GIP dual agonist.

To watch the video series component of this episode, click here.

1:00 Effect of incretins on blood glucose and body weight

3:24 Evolution of GLP-1 agonists

7:45 Mechanism of tirzepatide- dual GLP-1/GIP agonist

10:35 Overview of SURPASS and SURMOUNT trials for tirzepatide

17:45 Benefits vs. risks of GLP-1 agonists

21:45 Sustainability of weight loss with incretin-based therapies

25:30 Future of metabolic diseases management

Related Videos
Optimizing Diabetes Therapies with New Classifications
Helen Colhoun, MD | Credit: University of Edinburgh
Should We Reclassify Diabetes Subtypes?
What Should the American Academy of Physician Associates Focus on in 2025?
GLP-1 Agonist Safety Risks and Obesity Stigma with Kevin Peterson, MD, MPH
Roger S. McIntyre, MD: GLP-1 Agonists for Psychiatry?
Payal Kohli, MD | Credit: Cherry Creek Heart
Daniel Gaudet, MD, PhD | Credit: American College of Cardiology
Ana Maria Lopez, MD, MPH | Credit: Jefferson Health
Laxmi Mehta, MD | Credit: American Heart Association
© 2024 MJH Life Sciences

All rights reserved.